WO2024256710A3 - Constructions polypeptidiques de lysine modifiées actives contre des bactéries à gram négatif - Google Patents

Constructions polypeptidiques de lysine modifiées actives contre des bactéries à gram négatif Download PDF

Info

Publication number
WO2024256710A3
WO2024256710A3 PCT/EP2024/066700 EP2024066700W WO2024256710A3 WO 2024256710 A3 WO2024256710 A3 WO 2024256710A3 EP 2024066700 W EP2024066700 W EP 2024066700W WO 2024256710 A3 WO2024256710 A3 WO 2024256710A3
Authority
WO
WIPO (PCT)
Prior art keywords
engineered
negative bacteria
lysin
gram
active against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2024/066700
Other languages
English (en)
Other versions
WO2024256710A2 (fr
Inventor
Raymond Schuch
Xavier Vila Farres
Steven Swift
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aurobac Therapeutics SAS
Original Assignee
Aurobac Therapeutics SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aurobac Therapeutics SAS filed Critical Aurobac Therapeutics SAS
Publication of WO2024256710A2 publication Critical patent/WO2024256710A2/fr
Publication of WO2024256710A3 publication Critical patent/WO2024256710A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4723—Cationic antimicrobial peptides, e.g. defensins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/22—Klebsiella
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/38—Pseudomonas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/425—Serratia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente divulgation concerne une lysine modifiée comprenant : (a) une lysine de base à Gram négatif ; et (b) un ou plusieurs peptides antimicrobiens (AMP) et/ou un peptide de pénétration cellulaire (CPP), et éventuellement un motif de liaison à la membrane externe et au moins un lieur, ou un fragment actif de celle-ci, ou un variant de celle-ci ayant au moins 80 % d'identité de séquence. L'invention concerne également des méthodes de traitement d'une infection bactérienne provoquée par au moins une bactérie à Gram négatif et des méthodes d'élimination d'au moins une bactérie à Gram négatif, comprenant l'administration de la lysine modifiée décrite ici.
PCT/EP2024/066700 2023-06-15 2024-06-14 Constructions polypeptidiques de lysine modifiées actives contre des bactéries à gram négatif Ceased WO2024256710A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508506P 2023-06-15 2023-06-15
US63/508,506 2023-06-15

Publications (2)

Publication Number Publication Date
WO2024256710A2 WO2024256710A2 (fr) 2024-12-19
WO2024256710A3 true WO2024256710A3 (fr) 2025-01-16

Family

ID=91616925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2024/066700 Ceased WO2024256710A2 (fr) 2023-06-15 2024-06-14 Constructions polypeptidiques de lysine modifiées actives contre des bactéries à gram négatif

Country Status (1)

Country Link
WO (1) WO2024256710A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
US12686847B2 (en) 2023-04-19 2026-07-21 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191633A2 (fr) * 2018-03-29 2019-10-03 Contrafect Corporation Constructions polypeptidiques de lysine-peptide antimicrobien (amp), lysines, polynucléotides isolés les codant et utilisations correspondantes
WO2020046747A1 (fr) * 2018-08-23 2020-03-05 Contrafect Corporation Constructions polypeptidiques de lysine-peptide antimicrobien (amp), lysines, polynucléotides isolés les codant et leurs utilisations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8108587A (en) 1986-10-08 1988-05-06 David Bernstein Method for exposing group a streptococcal antigens and an improved diagnostic test for the identification of group a streptococci
AU2003247881A1 (en) 2002-07-08 2004-01-23 Joe S. Wilkins Jr. Antibacterial formulations
ES2934714T3 (es) 2015-09-17 2023-02-24 Contrafect Corp Polipéptidos de lisina activos contra bacterias Gram-negativas

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019191633A2 (fr) * 2018-03-29 2019-10-03 Contrafect Corporation Constructions polypeptidiques de lysine-peptide antimicrobien (amp), lysines, polynucléotides isolés les codant et utilisations correspondantes
WO2020046747A1 (fr) * 2018-08-23 2020-03-05 Contrafect Corporation Constructions polypeptidiques de lysine-peptide antimicrobien (amp), lysines, polynucléotides isolés les codant et leurs utilisations

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GERSTMANS H. ET AL: "A VersaTile-driven platform for rapid hit-to-lead development of engineered lysins", SCIENCE ADVANCES, vol. 6, no. 23, 3 June 2020 (2020-06-03), US, pages eaaz1136, XP055779045, ISSN: 2375-2548, DOI: 10.1126/sciadv.aaz1136 *
GHOSE CHANDRABALI ET AL: "Gram-Negative Bacterial Lysins", ANTIBIOTICS, vol. 9, no. 2, 11 February 2020 (2020-02-11), pages 74, XP055800842, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7168136/pdf/antibiotics-09-00074.pdf> DOI: 10.3390/antibiotics9020074 *
LIM JEONGHYUN ET AL: "Eradication of drug-resistant Acinetobacter baumannii by cell-penetrating peptide fused endolysin", JOURNAL OF MICROBIOLOGY, THE MICROBIOLOGICAL SOCIETY OF KOREA, SEOUL, vol. 60, no. 8, 25 May 2022 (2022-05-25), pages 859 - 866, XP037921945, DOI: 10.1007/S12275-022-2107-Y *
SCHWUDKE DOMINIK ET AL: "Broad-Host-Range Yersinia Phage PY100: Genome Sequence, Proteome Analysis of Virions, and DNA Packaging Strategy", JOURNAL OF BACTERIOLOGY, vol. 190, no. 1, 1 January 2008 (2008-01-01), US, pages 332 - 342, XP093212349, ISSN: 0021-9193, Retrieved from the Internet <URL:https://journals.asm.org/doi/pdf/10.1128/JB.01402-07> DOI: 10.1128/JB.01402-07 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12686847B2 (en) 2023-04-19 2026-07-21 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation

Also Published As

Publication number Publication date
WO2024256710A2 (fr) 2024-12-19

Similar Documents

Publication Publication Date Title
AU2019222918B2 (en) Antimicrobial peptides and methods of use thereof
Kosikowska et al. Antimicrobial peptides (AMPs) as drug candidates: a patent review (2003–2015)
Qian et al. Battacin (Octapeptin B5), a new cyclic lipopeptide antibiotic from Paenibacillus tianmuensis active against multidrug-resistant Gram-negative bacteria
WO2022272033A3 (fr) Protéines de contact avec des cellules immunitaires à libération prolongée et procédés de traitement
BR112021025948A2 (pt) Polipeptídeos antimicrobianos derivados de bacteriófagos e seu uso contra bactérias gram-negativas e ácido-resistentes
ZA200504804B (en) Topical anti-infective formulations
ATE543831T1 (de) Antibakterielle wirkstoffe enthaltende konjugate von glykopeptiden und membranassoziierenden peptiden
CA2957056A1 (fr) Peptides antimicrobiens cibles selectivement et leur utilisation
WO2018155813A3 (fr) Nouvelle protéine antibactérienne efal-2 ayant une capacité bactériolytique enversenterococcus faecium
MX2020010071A (es) Polipeptidos anti-microbianos, derivados de bacteriofago, y sus usos contra bacterias gram negativas.
US20160022832A1 (en) Proteas stabilized antibacterial peptides for s. aureus
MX2020008860A (es) Lisinas plyss2 modificadas y sus usos.
KR20180052178A (ko) 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 1 및 그의 조성물
TWI403330B (zh) 低血球溶解性之抗微生物胜肽、醫藥組成物及其用途
ATE259654T1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
KR101889396B1 (ko) 흰점박이꽃무지에서 유래한 항균 펩타이드 프로테티아마이신 2 및 그의 조성물
CA2707093A1 (fr) Thuricine cd, un antimicrobien pour cibler specifiquement clostridium difficile
WO2020232471A3 (fr) Méthodes et compositions comprenant des variants de protéine a (spa) de staphylococcus
KR101953828B1 (ko) 왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 1 및 그의 조성물
Leonard et al. Insights into antimicrobial peptides in fighting anthrax: A review
MX2023011235A (es) Construcciones de amurinas, lisinas y peptido antimicrobiano de lisina (amp) activas contra bacterias gram negativas.
WO2023034515A3 (fr) Administration d&#39;oligomères antisens par des peptides d&#39;image miroir
US20060258596A1 (en) Antimicrobial agents
KR101953834B1 (ko) 왕귀뚜라미에서 유래한 항균 펩타이드 테레오그릴루신 2 및 그의 조성물
WO2022115510A8 (fr) Peptides antimicrobiens et procédé de prévention ou de traitement d&#39;une infection à l&#39;aide de ceux-ci

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24734845

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 24734845

Country of ref document: EP

Kind code of ref document: A2